Windlas Biotech
Windlas Biotech Limited is an Indian pharmaceutical CDMO founded in 2001 that contract-manufactures pharmaceutical, nutraceutical, and ayurvedic products for B2B clients. Headquartered in Dehra Dun with 1,001-5,000 employees, it is listed on India's NSE and earns revenue via contract manufacturing fees.
- Company typePublic
- Founded2001
- HeadquartersDehra Dun, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Windlas Biotech does
Windlas Biotech Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) founded in 2001 and headquartered in Dehra Dun, India. The company manufactures pharmaceutical, nutraceutical, and ayurvedic products on a contract basis for third-party clients. It operates as a public limited company listed on India's National Stock Exchange (NSE) with a workforce of 1,001-5,000 employees, and is described in source material as a for-profit enterprise with no identified parent entity.
The company's core business is providing end-to-end contract development and manufacturing services to pharmaceutical and wellness-product companies seeking outsourced production capacity. Its product surface spans three categories — pharmaceutical formulations, nutraceuticals, and ayurvedic products — providing cross-segment exposure across regulated and traditional medicine formats. Underlying capabilities center on pharmaceutical formulation, scale-up, and commercial manufacturing, with distribution conducted exclusively through direct B2B sales to enterprise clients in the domestic Indian market; no international operations, channel partnerships, or app/digital platform presence were disclosed in the available source material.
Windlas generates revenue through a professional services-oriented model, collecting manufacturing and development fees from clients, though specific pricing structures are not publicly disclosed. The company addresses outsourced manufacturing needs for pharmaceutical firms requiring external development and production capability, with a stated horizontal segmentation approach (i.e., serving a broad base of customers across categories rather than concentrating in a single vertical). Its value proposition is functional rather than differentiated: it competes as a domestic multi-category CDMO rather than via proprietary technology, brand differentiation, or specialized regulatory positioning, and the available source material discloses no specific competitive differentiators or quantifiable customer outcomes.
Windlas Biotech firmographics
Firmographics- Name
- Windlas Biotech
- Legal name
- Windlas Biotech Limited
- Website
- https://windlas.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Windlas Biotech Limited is an Indian pharmaceutical CDMO founded in 2001 that contract-manufactures pharmaceutical, nutraceutical, and ayurvedic products for B2B clients. Headquartered in Dehra Dun with 1,001-5,000 employees, it is listed on India's NSE and earns revenue via contract manufacturing fees.
- Ownership category
- akta.pro rank
Windlas Biotech industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Windlas Biotech is headquartered
LocationHeadquarters
- HQ city
- Dehra Dun
- HQ country
- India
- HQ region
- Asia
Markets served
Windlas Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Windlas Biotech operates as a pharmaceutical CDMO providing contract development and manufacturing services. Revenue generated through manufacturing fees for pharmaceutical products developed for clients.
Distribution channels1 record
Windlas Biotech product offering
Product offeringCore offering
Windlas Biotech is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing contract development and manufacturing services for pharmaceutical, nutraceutical, and ayurvedic products. The company manufactures products on behalf of third-party clients, generating revenue through manufacturing fees. It operates as an end-to-end outsourced manufacturing partner for pharmaceutical companies.
Product overview
Windlas Biotech is a pharmaceutical contract development and manufacturing organization (CDMO) that develops and manufactures pharmaceutical products for third-party clients. The source material does not provide detailed information about specific product brands, modules, or named offerings beyond this general description.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Development and Manufacturing Services (CDMO) End-to-end pharmaceutical contract development and manufacturing services for third-party clients, covering formulation development and production of pharmaceutical products. Targeted at pharmaceutical companies seeking outsourced manufacturing capacity.
- Nutraceutical Product Manufacturing Contract manufacturing of nutraceutical products for client companies, providing formulation and production capacity for dietary supplements and nutritional formulations.
- Ayurvedic Product Manufacturing Contract manufacturing of ayurvedic formulations and traditional medicine products for client companies requiring production capacity in the traditional-medicine segment.
Companies that use Windlas Biotech
Customer profileIdeal customer profiles1 record
Windlas Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Windlas Biotech partnerships and signals
Strategic signalScale indicators8 records
Recent moves3 records
Expansion highlights3 records
Windlas Biotech competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is the world's largest pharmaceutical CDMO offering end-to-end drug substance and drug product manufacturing globally. As a broad incumbent it anchors the global CDMO benchmark for services, scale, and regulatory reach relevant to Windlas's potential global expansion.
- Aurobindo Pharma: Aurobindo Pharma is one of India's largest generic pharmaceutical manufacturers with a sizable contract manufacturing business across formulations and APIs. While much larger than Windlas, it competes for similar pharma CDMO contracts and is a relevant broad industry peer.
Direct peers
- Laurus Labs: Laurus Labs is an Indian-listed pharmaceutical manufacturer and CDMO with strong APIs and formulation capabilities serving global generics and innovator customers. It competes with Windlas for pharma contract manufacturing clients, particularly in APIs and oral solids.
- Syngene International: Syngene International is India's largest listed CRO/CDMO offering integrated drug discovery, development, and manufacturing services to global pharma clients. It is the most directly comparable Indian-listed peer to Windlas Biotech given its pharmaceutical contract development and manufacturing mandate at similar scale.
- Hikal: Hikal is an Indian-listed fine chemicals and pharmaceutical CDMO manufacturer of APIs and intermediates serving pharma and agro customers. It is comparable to Windlas as a domestic CDMO with overlapping contract manufacturing capabilities.
- Neuland Laboratories: Neuland Laboratories is an India-listed pharmaceutical CDMO offering contract development and manufacturing of APIs and intermediates, including peptides. Comparable to Windlas as a focused pharma CDMO serving global innovator customers from India.
- Suven Pharmaceuticals: Suven Pharmaceuticals is an India-listed CDMO providing contract development and manufacturing services for APIs and intermediates to global pharma clients. Like Windlas, it is a focused Indian CDMO with comparable scale and target customers.
- Piramal Pharma Solutions: Piramal Pharma Solutions is the CDMO arm of Piramal Pharma offering end-to-end contract development and manufacturing across drug substance and drug product. It is highly comparable to Windlas in scope (full-service pharma CDMO) though larger and backed by the diversified Piramal group.
- Divis Laboratories: Divis Laboratories is a leading Indian API and intermediates manufacturer with significant CDMO/contract research exposure to global innovator pharma. Comparable to Windlas as an India-based pharma contract manufacturer serving international customers.
Emerging players
- Cohance Lifesciences: Cohance Lifesciences is an India-listed CDMO formed via the merger of the API/CDMO businesses of Laurus Labs and other entities, offering contract development and manufacturing across APIs and formulations. It is comparable in scope to Windlas as a domestic pharmaceutical CDMO.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Windlas Biotech social profiles
Digital presenceWindlas Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Windlas Biotech leadership team
Management profileNumber of profiles
Profiles1 record
Windlas Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Windlas Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Windlas Biotech
What does Windlas Biotech do?
Windlas Biotech is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing contract development and manufacturing services for pharmaceutical, nutraceutical, and ayurvedic products. The company manufactures products on behalf of third-party clients, generating revenue through manufacturing fees. It operates as an end-to-end outsourced manufacturing partner for pharmaceutical companies.
Is Windlas Biotech a public or private company?
Windlas Biotech is a public company. It is classified as public and is currently operating.
When was Windlas Biotech founded?
Windlas Biotech was founded in 2001. It employs 1,001 to 5,000 people.
Where is Windlas Biotech based?
Windlas Biotech is headquartered in Dehra Dun, India, in the Asia region.
How does Windlas Biotech make money?
One revenue line is on record: contract Manufacturing Services.
Who are Windlas Biotech's main competitors?
Broad incumbents on record are Lonza Group and Aurobindo Pharma. Direct peers are Laurus Labs, Syngene International, Hikal, Neuland Laboratories, Suven Pharmaceuticals, Piramal Pharma Solutions and Divis Laboratories. Cohance Lifesciences is listed as an emerging player.
Does Windlas Biotech have an API?
No public API is recorded for Windlas Biotech.
What industry is Windlas Biotech in?
Windlas Biotech's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its SIC code is 8731.